Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
• معرفتنا وإطالعنا عللى نظام الرعاية • نقترح تطبيق خطة عمل من 4خطوات إلعداد • تشهد المملكة في الوقت الحالي جهود مكثفة
الصحية في المملكة ورؤيتها في تحويله االستراتيجيات الوطنية ،يدعمه فريق متخصص لتحويل نظام الصحة بهدف تحسين قابلية
وتطويره –عالوة على خبراتنا الواسعة في ومتفرغ لمدة 4أشهر: الوصول إلى خدمات الرعاية ورفع مستوى
تطبيق نماذج الرعاية الصحية ووعينا التام – استيعاب التوقعات والطموحات جودة الخدمات وضمان استدامتها
بالتحديات القائمة وأهداف الخدمات السريرية – تقييم الوضع الحالي والنماذج المستقبلية ي ف الصحة وزارة • وفي سياق تلك الجهود ،تقوم
• سيتم التحقق من منهجنا من خالل الزيارات الوقت الحالي بتطبيق نموذج الرعاية الجديد
تدريجيا بهدف توفير خدمات الرعاية المتكاملة – وضع تفاصيل االستراتيجية
الميدانية والممارسات الدولية المثلى حرصاً
على التطبيق األمثل للمنهج – خطة التنفيذ والتقييم • ولذلك ،تستهدف وزارة الصحة الحصول على
• منهجنا يتطلع للمستقبل ويستند إلى قدرات • تغطي خطة العمل كافة المراحل بدءاً من المساندة في إعداد استراتيجية وطنية لعالج
االستشراف التي تدعمها الدراسات الدولية الوقاية والتشخيص وصولً إلى مرحلة ما بعد مرض السرطان والصحة الذهنية سعياً نحو
المعتمدة العالج تحسين الخدمات السريرية والوصول بها من
• وخالل مراحل تنفيذ المشروع ،سوف نستفيد من مرحلة الخدمات األساسية إلى خدمات
• سوف نشرك كافة الجهات ذات الصلة حرصاً متخصصة.
على التعاون البناء وتقبل النتائج سريعاً الجهود السابقة والفجوات التي تم تحديدها
باإلضافة إلى فهم توقعات المرضى واألطباء بعض تحديد تم ،المبدئي التقييم إلى • وبالنظر
• لقد نفذ خبراؤنا مشاريع مماثلة -في المملكة التحديات في توفير تلك الخدمات السريرية مثل :والجهات ذات الصلة بهدف حصر المتطلبات
المتحدة وإيطاليا وكندا والخليج وغيرها . واالحتياجات والفجوات التي يجب تلبيتها عدم دقة التشخيص ،عدم القدرة على الوصول
وخبراتنا تشمل أفضل التجارب الطبية من إلى العالج بالشكل األمثل ،وجود فجوات في
مختلف أنحاء العالم. • ولذلك ،قمنا بتحديد فريق من الخبراء يشمل
شركاء وخبراء متخصصين واستشاريين آخرين الخدمات المتخصصة ،ضعف التغطية
• نضمن مسؤوليتنا في كافة مراحل المشروع ممن لديهم معرفة وخبرات واسعة في نظم ال المج الجغرافية ،عدم كفاية العاملين في هذا
وقابلية تنفيذه من خالل االختبار المشترك الرعاية الصحية من مختلف أنحاء العالم. وارتكازهم في موقع واحد ،عالوة على التنوع
لمقترحاتنا الشديد في توفير األدوية وغيرها...
A.T. Kearney XX/ID 3
Agenda
• Overview
• Our understanding of the context
• Proposed project approach and methodology
• Project Timeline
• Leadership commitment, project team and subject matter experts
• Why A.T. Kearney
“We intend to provide our health care through public corporations both to
enhance its quality and to prepare for the benefits of privatization in the
longer term. We will work towards developing private medical insurance to
improve access to medical services and reduce waiting times for
appointments with specialists and consultants”.
Planned Care
Physical wellbeing Mental wellbeing
What are the benefits of the new
Model of Care?
Social wellbeing
Five Corporates
Chronic Care
Planned Care
Physical Mental
Integrated Clusters wellbeing wellbeing
Social wellbeing
Highly Specialized
Hospital
Hospital
• Conditions that require specialized • Screening and post-acute services for rare
equipment and special skills. conditions
Geographic
• National services
• Services provided within the cluster
• Coverage for one or more regions
boundaries
• Community services
Layers of
• KSA is facing challenges in the delivery of specialized care, areas of opportunity have been identified
in the role of primary care to improve diagnose, the quality of services and the breadth and availability
The situation of services
and ask
• The Ministry of Health has requested support to develop national strategies for Oncology and Mental
Health services to improve access and quality of care across the Kingdom
Mental
health WHO should provide The Services?
3 3 (role of different ministries, direct provision vs commissioning, use of
and private sector, role of Clusters, governance, etc.)
oncology
Summary of experience Summary of experience Summary of experience Summary of experience Summary of experience
• Head of EMEA • Over 20 years of industry • Over 20 years of • More than 8 years of • Over 9 years of industry
Healthcare Provider, and and consulting experience management consulting consulting and industry and consulting and
Head of Change Mgt with focus healthcare experience in biopharma experience industry experience
sector and healthcare strategy
Areas of expertise Areas of expertise Areas of expertise Areas of expertise Areas of expertise
• Leading or co-leading our • Design of improvements • Has broad experience • Worked with regional • Researched the GCC
support to the MoH in a for clinical and operational across disease hospital system to pharmaceutical and
GCC country to develop a processes for the NHS categories, with particular evaluate its cancer medical devices market,
new healthcare financing • Development and depth in oncology and services epidemiology and
model and to redesign the implement of commercial immunology. • Proposed structure, healthcare systems with
policy for the UK focus specialized care
provider base • Has worked in clinical, organisation and
Department of Health regulatory, and technology requirements • Carried out 50 + market
• Formerly led our support • Worked on information for developing regional research projects,
for many years to the UK commercial strategy in
strategy issues for Health most major geographies cancer centre after including multiple studies
National Heath Service and the Department of reviewing of cancer with focus on care
• Led major transformations pathways and patient
• Spported large complex Health Strategy
of portfolio management centres across the region
journeys of cancer,
transformations in public • Helped to redesign the and R&D decision-making • Created a cancer depression and autism
and private sectors in supply chain of the NHS, processes over the last pathway in collaboration
health, defence, postal, and help set the DH’s decade with a healthcare provider • Supported MoC Dammam
and other sectors approach and its key partners Pilot
Health Practice Health Practice Health Practice Project Manager Project Manager
EMEA EMEA North America (Option 1) (Option 2)
Project team will also gain insight and support by our external
experts network, with specific focus on relevant segments
A.T. Kearney external SME network - Selected profiles1
Phil Hope Olga Laskina William Hyslop
Mental Health expert Mental Health expert Oncology expert
• Held the position of Minister of State for Care • For School Health in Russia, developed and • More than 40 years of experience in
healthcare serving in leading positions
Services in the Department of Health tested a correction program for children with
• Supported in the development of National learning disabilities • Led the development of the MD Anderson
Mental Health Strategy in UK, National Autism • Developed a screening program and education Cancer Network as a leading cancer
Strategy, National Dementia Strategy as well as program for teachers to screen mentally academic affiliate network in UK
National Care Service White Paper distressed students • Served as CEO of three general acute care
• Development of the National Care Service • For an NGO, developed and implemented an hospitals
White Paper, the National Dementia Strategy, education program for families bringing up
the National Mental Health Strategy, and the children with autism • Several engagement related to
transformation and setting national healthcare
National Autism Strategy. • For State penitentiary system, developed a
strategy at the country level
• Delivered several lectures or seminars for the program facilitating adaptation of ex-convicts to
Global Health Innovation . live in the society
• Appointed as CEO of Dana Farber Cancer • 15 years of experience of business and strategy
Institute / Harvard Cancer Center • 20+ years of healthcare consultation across
experience in pharmaceutical and biotechnology Europe and UK
• Focuses on research related to finding methods industry with focus on targeted therapies in
to combatting cancers from within the human oncology • Supported in development of several national
immune system and international studies related to
• Led a transformation in cancer care where each specialized care, telemedicine, urology,
• Worked on identifying innovative ways of patient’s cancer can be treated at the level of its emergency, medicine and primary care
treating cancer to increase the patient expected molecular blueprint delivery
age • Led the establishment of a molecular • Assessed Patient Access Schemes for
• Supported several initiatives related to information company which support a specialized care including oncology
improving patient outcome transformation in cancer by providing a unique
cancer treatment based on a deep • Ran the interventional procedures program
• Awarded with several awards for her and set up commissioning through evaluation
discoveries in achievement in oncology understanding of the genomic changes
and observational data unit initiatives
1. Depending on project start date and availability A.T. Kearney XX/ID 14
Source: A.T. Kearney
Overview
Schizophrenia, schizotypal and delusional disorders ~40-50% of the population ~75% of Mental
of the USA and EU suffer Disorders onsets before
from at least 1 Mental
Mood [affective] disorders
Disorder in their lifetime the age of 24
• Systematic • MoH
post-grad announced
training in plans to create
psychiatry psy wards in 45
established government
hospitals
A.T. Kearney XX/ID
Source: Centre for Science, Knowledge and Belief in Society, Newman University, Birmingham, International Journal of Psychiatry in Medicine, Open Journal of Psychiatry 19
Our understanding of the context – Mental Health
1 4 80 to 85% of
Under-
Segregation treatment
diagnostics 50 to 90% of Primary Care delivered in
and symptomatic of somatic
specialty care
suboptimal patients are and mental
Schools & facilities, where
access to missed Secondary treatment
University physical treatment
treatment care
is not available
2 Lack of 5
Metal Health holistic Large segments
Gaps in
services are approach to with no access to
Lack of specialty
currently not integrate specialty care
School services and
available at patients into (children, women,
Mental Health geographical
schools (there is society geriatric patients
coverage
a Pilot running) etc..)
3 6 Primary care
Lack of Community
Community & Specialty care Restrictions physicians have
understandin resources such
NGOs very restricted
g and as support in
rights to
support groups are psychotropic prescription;
within largely not medication supplies are also
communities available Pharmacotherapy restricted
Source: A.T. Kearney, interviews, Mental Health Phase 2 Report A.T. Kearney XX/ID 21
Our understanding of the context – Mental Health
5
• Increasing number of private providers and NGO’s providing Mental
Health relief services
55% 55%
47% 49%
Records of 41% 42%
50 GP’s
Source: Trends in GP prescribing of psychotropic medication, BMC Psychiatry psychotropic medications A.T. Kearney XX/ID 25
Our understanding of the context – Mental Health
Source: National Association of School Psychologists, American Psychiatric Association, Washington Post A.T. Kearney XX/ID 26
Our understanding of the context – Mental Health
Average
• Improves processing skills, by 85
combining game and learning Before After
Fast 80
• It is adaptive, meaning students move
ForWord
from slow and easy speech patterns to 75
Software normal speed at their own pace
• Engaging and fun for autistic children 70
Average
Below
65
Child with
START psychotic
symptoms
Primary
Patients hospitalized
Patients with somatic with SMI, having severe
complications of mental physical comorbidities
disorders
Male Female
• Footprint and referral process
should promote universal access
Pediatric Pediatric
population: population: • Facilities should cover all
segments including forensic and
Male Female prison healthcare
Gender
Integrated
support
• What should be the scope and objectives of the Mental Health System in KSA?
Scope of services • What is the list of key gaps that need to be prioritized and bridged in the next 12
months? 3 years?
Cancer is among the leading causes of death worldwide. The burden of the
disease is high and awareness important to inform local cancer strategies
1000 Beds
15,807 patients
Paediatric
Radiation
oncology
oncology
oncology
oncology
Palliative
medicine
Haemat-
Surgical
Medical
Nuclear
Provider
ology
BMT
care
King Fahad Medical City
Riyadh ✓ ✓ ✓ ✓✓ ✓ ✓ ✓ ✓
System
gaps
Unavailability
of specialized
care Cost & burden
of disease
A
Several issues are currently faced in the system including pre-treatment services, service distribution,
skilled workforce and supply of medications
B
Several specialized services are not currently available with KSA with improvements
required on others
C
Disease cost is increasing with expectation of an increase in the
prevalence: SAR 400k is spent per patient sent abroad
Recovery
Primary Detection & Triage &
Treatment /Remission /End
prevention screening Diagnosis
of life
Immunisations Genetic screening for
Palliative care / Clinics
against HBV, HPV hereditary cancer
Smoking prevention & Breast cancer Haematology
Clinical examination Monitoring
cessation screening oncology
Obesity & healthy Cervical cancer
Medical imaging Paediatric oncology Survivorship
eating advice screening
Services
1 • Survival rates dramatically improve when early diagnose allows the disease to
be confined to the organ of origin
Prevention/ • Cancer prevention and control programs in UK is done through National
Early
2 Diagnose
Cancer Institute
• UK and Australia have a centralized program for screening population based
specific criteria
1. Saving lives, averting costs. Cancer Research UK. September 2014 A.T. Kearney XX/ID 42
Our understanding of the context – Oncology
Key observations
• Multidisciplinary team
Screening Survivorship (MDT) is key to provide
appropriate treatment
Therapy cycles
decisions and plans
and regimes • Case coordinators1 are
Awareness of Diagnostic & changes Disease progression
Symptoms - Staging
the primary point of
Prevention contact within the MDT
to ensure
Health Hospital – Continuity of care
Treatment choices informatics avoidance – Patient centric approach
Workforce involvement – Reducing access barriers
Case coordinators – Patient education
(MDT)
– Patient adherence to
therapy
Nurse Oncologist Radiologist Nurses, hospices,
Nurse GP Multidisciplinary team
Chemotherapy Surgeon Palliative care
Multiple healthcare providers with no coordinated support increase the likelihood of care
fragmentation, contributing to ineffectiveness, inequality, less adherence and higher costs
1. Case coordinators may be referred to as care coordinators, case managers or patient navigators and are usually healthcare professionals
Source: A.T. Kearney A.T. Kearney XX/ID 44
Our understanding of the context – Oncology
Turn or council
Home Nuclear • Turn a silent killer into a know disease that can be fought
care methods
Cancer surgery
• Remove the tumour & surrounding tissue during operation
Approach to cancer Medical oncology
patients • Use chemo, hormonal, biological or targeted therapy
Patient Turn or Radiotherapy
follow-up council • Use waves of radiation to teat cancer and tumours
Patient follow-up
• Provide long term support to avoid cancer recurrence
Screening Treatment
NHS example
• National Cancer Institute in UK have designated cancer
center for cancer prevention and control programs
Palliative
– Early diagnosis and accessible treatment for cancer Prevention
care
are critical
Survivorship
– Effective interventions to prevent cancers exist and are care
‘Traditional’
Apps, platforms &
Examples
Neulasta can reduce infection • Enhanced symptoms tracking • Reduce the cost
risk by 94% when treated • Tracking of appointments • Improve health outcomes
Innovation in oncology treatments together with early diagnose has generated better
prognosis and longer life expectations in recent years
Source: IMS Health, R&D Focus, IMS Institute for healthcare informatics (May 2016); A.T. Kearney A.T. Kearney XX/ID 51
Our understanding of the context – Oncology
New value assessment frameworks have been developed 2011 2012 2013 2014 2015
by physicians and policy groups along with targeted population
Rest of the world Pharmerging Japan EUS US
As R&D advances produce longer life extensions, access to innovative treatment through
outcome based reimbursement will become a key capability of any health systems
Implications
• Stronger screening capabilities
• The use of predictive biomarkers has allowed sub-
populations within cancer types to be identified • Better access to innovative
Personalized therapies
• Overall, this trend has led to an increase in the
Medicine number of personalized medicines that can specifically • Skilled practitioners
target unique cancer populations • Holistic system to segment
patient populations
Supportive Care
PATIENT • Allows for integration of highly specialized cancer
treatment alongside local delivery while avoiding
unnecessary admissions to hubs
• Provides the required information and advice to support
Hospices and • Enable early detection and management of cancer
End of life support Follow up / complications
Survivorship services
Primary care, Home care
• Acute oncology services aim to improve patient safety, quality of care, and the coordination of
Specialized Care care for all patients irrespective of the place of care and admission route
(National / Regional • The recommendation to further consolidate services is based on the relationship between
hubs) volumes and outcomes and on the wider ambition to provide high quality acute services
• The relationship between specialized and localized services should be balanced to allow
enough volumes for clinical expertise and sufficient local access for patient support
• Clinicians involved in acute oncology will have a critical role in delivering training and education
to all health-care professionals in the wider system
• These outpatient services will need to incorporate extended hours of work and provide
ambulatory care / outpatient procedures
Supportive Care • These services will need to integrate alongside existing acute care services to maximize
(Cluster led) efficiency opportunities
• Capacity is a significant challenge in other areas of cancer care, such as community
chemotherapy and devolved follow-up for low-risk patients.
To improve the current state, KSA has set clear patient goals to
be achieved as part of the transformation program
Defined patient goals
Reduce
Centralizing complex surgery
complications
Patient
goals More effective treatment
Decrease length
Waiting time reduction
of stay
Improvement in referral process
Quicker diagnosis
Decrease mortality (e.g., improved access to PET scans)
rates Fewer complications
Goals need to further defined to be linked to clear and tangible and outcomes
Integrated
support
• How to improve diagnosis and early stages, ensure access to required care and
improve outcomes?
Approach • How to ensure patients get access to the right therapy / treatments?
• How to ensure access to supportive services complemented with a strong referral
pathway?
Focus on stakeholder • Our work is focused on engaging all key stakeholders to ensure
engagement collaboration and buy-in from day one
Validated by on-site • Our approach will be validated by on-site visits and international
visits and best practices best practices for pathway design
• Our global experts have done this – In UK, Italy, Canada, GCC, and
Informed by beyond. Our proposed SMEs bring the best insights from clinical
international experts services around the world
1.3
• Conduct interviews and / or launch a survey
• Evaluate patients demand drivers, satisfaction level, and • Patient perspective on:
Understand Patients
perspective on the public services for Oncology and Mental – Mental Health
Perspective And Needs Health – Oncology
• Identify list of
stakeholders to be
interviewed per area
Current system key components
To map the current state, we will collect the input from all layers
of care (currently operating in silos) and plot it on the pathways
1.1 Current state mapping Example – Mental Health
Map as-is for the sector in general and for pathways of top-10 most devastating mental
disorders (depression, anxiety, bipolar disorder, schizophrenia, dysthymia, eating disorders,
childhood behavioral disorders, ADHD, intellectual disability, substance abuse1)
1. Based on BMI DALY data for KSA, may be adjusted based on validated epidemiology and Client demand
Source: A.T. Kearney A.T. Kearney XX/ID 64
Proposed project approach and methodology
2.2
• Benchmark both sectors for provision, governance, target
Derive Lessons Learnt
population, services, private sector & funding • Benchmarks of mental health in
• Evaluate KSA context and cultural particularities comparable countries
for Best Practices and • Understand the ongoing transformation programs and • Benchmarks oncology in
Tailor to KSA Context evaluate the impact of best practices comparable countries
• Summarize the findings and provide perspective on services
Market visits and field studies offer insights into quantity and
quality of current service supplies
2.1 Supply & Demand Baseline: Market & Field visits Illustrative
Calculation logic:
Average incidence Average rate of BC
C2 women # Patients needed
rate of breast diagnosis / person
population to be tested
cancer in KSA tested
Calculation:
22.4 per 100,000 1.5 million Saudi by ~1680 patients/year
10% or lower
women 2020 * 50% women ~32 patients/week
Gaps: Few PHC’s offer the service, Location far from home, few No support groups /
50 to 90% of cases pharma supply is female wards are available community care close to
are missed interrupted home
Research will need to be focused on few key disorders to maintain focus and
achieve reliable and extrapolatable insight
…
• How can we measure the impact? ..
1. Alignment to
Core 1 2 4
Government Criteria 1 Criteria 2 Criteria 3
Mandate
2.
Implementation 2 2 2
Complexity Critera1 Criteria 2 Criteria 3
3. Cost Impact 1 3 4
on Government Criteria 1 Criteria 2 Criteria 3
4. Role of 2 3 4
Private Sector Criteria 1 Criteria 2 Criteria 3
5. Alignment
with Current 1 2 4
Throughout the process clinical leaders will be Transformation Criteria 1 Criteria 2 Criteria 3
enabled to design, challenge and test solutions to
support the whole health system Total 1 2 3
A clear, specific, compelling picture or image of what the system will be and what its defining
Vision attributes will be at a specific time in the future… It can include key results yet to be
accomplished and their expected impact
“A “vision” is therefore
Good Practices Typical Components a picture of a
preferred, desirable
future state that
• Aspirational, inspiring, energizing • Future oriented describes what the
statements describing the future state system will be like in
• Likely to lead to a better future some years from now.
• Crystallizing the rationale for It is a dynamic picture
achieving desired state by providing a • Reflects values of the future that
common, coherent strategic direction • Sets standards of excellence answers the question
“what do we really
• Asserting the systems outcomes to • Clarifies purpose and direction want?”
key stakeholders in ways that will
resonate with them • Inspire enthusiasm and commitment
• Concision, descriptiveness and clarity • Reflects the uniqueness
• Referring to a specific time in the • Ambitious
future
Strategic
Patient perspectives objectives Targets defined in
and objectives existing strategies
Outcome of gaps
Benchmark against
assessment vs
leading countries
future state
beyond
• Identify the right patient segments to strategy
• Be based on clear guidelines and governance for addresses Paediatric needs, Women specific
cross cluster activities as well as access to highly requirements and Geriatric needs among others
specialized centres
• De-stigmatize care and increase awareness to mental
• Provide an optimal delivery model in terms of health conditions
National services and cluster led services that are
• Enable communities to dignify living conditions of
aligned with the Model of Care strategy
patients
• Enable private and third sector participation to
improve the delivery of Specialized Care
• Deliver a sustainable model to ensure future Oncology Strategy
capability development based on population needs
• Understand the specific needs of children and
• Be based on best practices, standards and clinical empower Paediatric services
guidelines
• Enable primary care to take a more relevant role in
• Determine what IT and digital systems will be preventing, screening and early diagnose
needed
• Develop an Oncology model that ensures equitable
• Be aligned with all other transformational programs access to primary services, supportive care and
(Corporatization, Model of Care, Workforce, specialized care
eHealth, etc.)
Benchmarks will be used to design the governance and define the roles and
responsibilities of the different stakeholders
Delivery assumptions
■ We have planned a collaborative work with the VRO team, both to create the opportunity for applied learning to deepen
their capability development and to help go deep on the assessment and design of the new strategies. We assume there
will be a core team of Saudi Nationals fully dedicated to the delivery of this engagement, and that people selected for the
roles will bring enthusiasm for the transformation, deep knowledge of and commitment to the MoH system, specially about
the implementation of a new Model of Care
■ While we commit to provide our support in accordance with best industry practice, the success of the project will ultimately
be the result of the joint efforts of the talented people of MoH along with the A.T. Kearney team. The MoH’s ability to create
a widespread momentum and organisational commitment is key to successfully develop and implement the new strategies
for Specialized Care in Oncology and Mental Health
■ Successful delivery of the project within the timelines assumes timely decision making and approvals on the agreed model
and strategies from the VRO leadership, especially the outcomes of the workshops highlighted in the timeline. Attendance
to workshops and leadership sessions is critical for the success of the project
■ Interviews with main stakeholders should take place early in the process to provide initial hypothesis on the strategic
opportunities. Working sessions with clinicians should also be planned well in advance as their availability can be
problematic
■ It is also assumed that the teams will work on a positive environment that enables constructive challenge through expert
opinion and external references as well as internal analysis of the current situation, ambitions and expected outcomes
We will jointly work with MoH VRO team to ensure that the
design of national strategy for mental health and oncology
Proposed project organization with significant senior involvement For Discussion
Note: A.T. Kearney delivery team staffing will be finalized on confirmation of project start date
Source: A.T. Kearney A.T. Kearney XX/ID 88
Leadership commitment & project team
Project Team1
Summary of experience Summary of experience Summary of experience Summary of experience Summary of experience
• Head of EMEA • Over 20 years of industry • Over 20 years of • More than 8 years of • Over 9 years of industry
Healthcare Provider, and and consulting experience management consulting consulting and industry and consulting and
Head of Change Mgt with focus healthcare experience in biopharma experience industry experience
sector and healthcare strategy
Areas of expertise Areas of expertise Areas of expertise Areas of expertise Areas of expertise
• Leading or co-leading our • Design of improvements • Has broad experience • Worked with regional • Researched the GCC
support to the MoH in a for clinical and operational across disease hospital system to pharmaceutical and
GCC country to develop a processes for the NHS categories, with particular evaluate its cancer medical devices market,
new healthcare financing • Development and depth in oncology and services epidemiology and
model and to redesign the implement of commercial immunology. • Proposed structure, healthcare systems with
policy for the UK focus specialized care
provider base • Has worked in clinical, organisation and
Department of Health regulatory, and technology requirements • Carried out 50 + market
• Formerly led our support • Worked on information for developing regional research projects,
for many years to the UK commercial strategy in
strategy issues for Health most major geographies cancer centre after including multiple studies
National Heath Service and the Department of reviewing of cancer with focus on care
• Led major transformations pathways and patient
• Supported large complex Health Strategy
of portfolio management centres across the region
journeys of cancer,
transformations in public • Helped to redesign the and R&D decision-making • Created a cancer depression and autism
and private sectors in supply chain of the NHS, processes over the last pathway in collaboration
health, defence, postal, and help set the DH’s decade with a healthcare provider • Supported MoC Dammam
and other sectors approach and its key partners Pilot
Health Practice Health Practice Health Practice Project Manager Project Manager
EMEA EMEA North America (Option 1) (Option 2)
Project team will also gain insight and support by our external
experts network, with specific focus on relevant segments
A.T. Kearney external SME network - Selected profiles1
Phil Hope Olga Laskina William Hyslop
Mental Health expert Mental Health expert Oncology expert
• Held the position of Minister of State for Care • For School Health in Russia, developed and • More than 40 years of experience in
healthcare serving in leading positions
Services in the Department of Health tested a correction program for children with
• Supported in the development of National learning disabilities • Led the development of the MD Anderson
Mental Health Strategy in UK, National Autism • Developed a screening program and education Cancer Network as a leading cancer
Strategy, National Dementia Strategy as well as program for teachers to screen mentally academic affiliate network in UK
National Care Service White Paper distressed students • Served as CEO of three general acute care
• Development of the National Care Service • For an NGO, developed and implemented an hospitals
White Paper, the National Dementia Strategy, education program for families bringing up
the National Mental Health Strategy, and the children with autism • Several engagement related to
transformation and setting national healthcare
National Autism Strategy. • For State penitentiary system, developed a
strategy at the country level
• Delivered several lectures or seminars for the program facilitating adaptation of ex-convicts to
Global Health Innovation . live in the society
• Appointed as CEO of Dana Farber Cancer • 15 years of experience of business and strategy
Institute / Harvard Cancer Center • 20+ years of healthcare consultation across
experience in pharmaceutical and biotechnology Europe and UK
• Focuses on research related to finding methods industry with focus on targeted therapies in
to combatting cancers from within the human oncology • Supported in development of several national
immune system and international studies related to
• Led a transformation in cancer care where each specialized care, telemedicine, urology,
• Worked on identifying innovative ways of patient’s cancer can be treated at the level of its emergency, medicine and primary care
treating cancer to increase the patient expected molecular blueprint delivery
age • Led the establishment of a molecular • Assessed Patient Access Schemes for
• Supported several initiatives related to information company which support a specialized care including oncology
improving patient outcome transformation in cancer by providing a unique
cancer treatment based on a deep • Ran the interventional procedures program
• Awarded with several awards for her and set up commissioning through evaluation
discoveries in achievement in oncology understanding of the genomic changes
and observational data unit initiatives
1. Depending on project start date and availability A.T. Kearney XX/ID 91
Source: A.T. Kearney
Agenda
• Overview
• Our understanding of the context
• Proposed project approach and methodology
• Project Timeline
• Leadership commitment, project team and subject matter experts
• Why A.T. Kearney
Experienced team • MoH will benefit from a senior and highly experienced
with intimate A.T. Kearney team supported by a global expert network
4 knowledge of MoH • Our team has intimate knowledge of all MoH relevant
key stakeholders stakeholders
1
A.T. Kearney is a leading global management consulting firm
1
A.T. Kearney is a leading global management consulting firm
with a strong global and Middle East footprint
A.T. Kearney overview
Clients We work with more than two-thirds of the
Fortune Global 500, the world’s largest
companies by revenues, as well as with the most
influential governmental and non-profit
organizations. Europe
Locations A.T. Kearney has 62 offices located in major • Amsterdam • Istanbul • Oslo
• Berlin • Kiev • Paris
business centers in more than 40 countries. • Brussels • Lisbon • Prague
• Bucharest • Ljubljana • Rome
Team We are 3,500 people strong worldwide who • Budapest • London • Stockholm
have broad industry experience and come from • Copenhagen • Madrid • Stuttgart
• Düsseldorf • Milan • Vienna
leading business schools. • Frankfurt • Moscow • Warsaw
• Helsinki • Munich • Zurich
1
In the Middle East, we have a strong presence, with six
established offices and over 200 consultants
A.T. Kearney presence in KSA and the Middle East
• Since 1926 globally and in the GCC for over 40 years
Turkey
• We hire locally and our Middle East consulting team
includes over 200 consultant with more than 70
Arabic speakers
Lebanon Kuwait
• Six established offices
– Riyadh, Dubai, Abu Dhabi, Manama, Doha, and
Bahrain Beirut
Saudi Arabia Qatar
- Riyadh • A.T. Kearney is strongly committed to the GCC and
Egypt U.A.E has completed 250+ projects
• Direct access to A.T. Kearney’s global network of
industry and functional experts, resources and
Oman methodologies
• Internationally experienced consultants
Formal Office
Operations
We leverage specific expertise of consultants from our global offices and work
in most countries in the region, including GCC countries, Lebanon, Jordan,
Iraq and Egypt
Source: A.T. Kearney A.T. Kearney XX/ID 96
Why A.T. Kearney
1
In the KSA, we have a strong presence, with the following
detailed personal information
A.T. Kearney information in KSA
Information
Legal name A.T. Kearney Saudi Limited - شركة ايه تي كيرني السعودية المحدودة
Type of Company / Establishment Limited Foreign
Address Al Khaiyria Building, South Tower, 7th Floor FS07A, King Fahad Road, Olaya,
P.O 25495 Riyadh 11466 KSA
Phone Tel. +966 (0) 11 290 5200, Fax.+966 (0) 11 206 1258
Staff at Tenderer Company / Robert Willen – Partner - Managing Director, Middle East
Establishment (Names & Positions) Mohamed Berrada – Partner (main contact)
Employees at main KSA office 10
Employees globally 3500
Work Permits (License) No 102031119005 issued at SAGIA
Date of issue 15/01/1430 Validity 10 years
Commercial Registration No 1010302463 issued at Ministry of Commerce and Industry dated: 03/03/1432
1
Our expertise spans a wide range of industries and services
What we do
Service Practices
Transformation
Organization &
Policy Council
Sustainability
Supply Chain
Operations &
Production &
management
Management
Marketing &
Technology
Information
Operations
Innovation
Strategy &
Business
and R&D
Sourcing
Strategic
Improv.
Growth
Global
Sales
Financial Institutions
Government &
Economic Development
Industry Practices
Travel, Transportation
and Infrastructure
Communications, Media
& Technology
Energy, Petrochemicals,
and Process
1
Our global organization is segmented by region…
Global Business
Chief Financial Chief Talent Chief Marketing
General Counsel Policy Council
Officer Officer Officer
R. Zeller P. Laudicina / E.
C. Laurens P. Morgan G. Singer
Peterson
1
…and our Middle East organization is segmented by practice
Finance Administration
HR IT
Strategy, Marketing
and Sales
Procurement &
Analytics Solutions
(PAS)
Operations
2
We supported in piloting the HTN and SCD pathways in the
Eastern cluster as well as the MoC roll-out
HTN & SCD pilot experience in Eastern… …and MoC roll-out
20+ Interviews & 10+ A.T. Kearney is supporting
Pilot toolkit
workshops the roll-out planning of the
Model of Care
3
We have a wide range of experience that can be leveraged
during our work for MoH
Our Relevant experience Selection of cases – Details in appendix
Pathway design
transformation
Mental Health
Model of care
management
Oncology /
Healthcare
Qualifications Country
Disease
1
For a mid-size EU provider of community and mental health services, we
performed a market assessment ✓ ✓ ✓ ✓
We supported in analysing the depression patient journey, identifying gaps
2 and providing recommendations ✓ ✓ ✓ ✓
3 For a leading medical player, we assessed the markets of 5 brain diseases ✓ ✓ ✓ ✓
4
We analyzed the patient journey for cancer treatment and proposed a new
approach ✓ ✓ ✓ ✓
5 For a Department of Health, we supported in designing the Cancer
Commission Toolkit as part of their reform strategy ✓ ✓ ✓ ✓ ✓
6
We helped identify partnering opportunities with the NHS to help improve
funding to cancer services ✓ ✓ ✓ ✓ ✓
We have defined the Clinical Regulatory Strategy for two lead compounds in
7 Oncology ✓ ✓ ✓
8 We developed a strategy for brain health for a leading healthcare player ✓ ✓ ✓ ✓ A.T. Kearney XX/ID 102
Source: A.T. Kearney
Why A.T. Kearney
Approach
Market analysis
and competition • Rapid market analysis aiming to provide key
market insights (but not intended to be
comprehensive)
a. Market analysis:
demand side
• High level market segmentation defined to
What are our market structure analysis
segments, their size
and growth? • Using existing fact base, interviews with
key stakeholders, and additional external
b. Market analysis: research where needed
supply side
How competitive is • Market analysis co-developed by trust team
each segment?
with external consulting support1
Purpose Approach
• Understand our market segments • Core market geography grouped into
distinct segments, aligned to how
• Gain a common understanding of
patients access services and how
local market size and growth
commissioners purchase and
− Size is a key indicator of market manage services
potential/attractiveness
• Fact-based estimates were used
− Growth indicates future size and when needed
determines market dynamics
• Growth estimated based on forward
projections and assumptions relating
to changes in underlying drivers (i.e.
patient needs and commissioner
funding)
Treatment
Patient in remission
cessation
Psychologist /
Psychosocial interventions Psychosocial interventions Continuing treatment
Therapist
Psychiatrist /
• Combine ADDs Management &
Specialist Mental Specialist / enhanced care
• Augment therapy continuing care
Health Services
Patient Associations
Aid recognition & self-diagnosis Raise awareness of options & “own” patient groups Continuing care
/ Social Care
Payers Develop / approve / enforce clinical guidelines and reimbursement / pricing decisions
ADDto
Difficult adjustment ADDto
predict response use Continue ADD use
Notice change in Inconsistent diagnosis of early Continuing monitoring &
GP / HCP ADD treatment leading to long
behaviour depression symptoms Diagnosis assessment
adjustment periodinterventions
Psychosocial Periodic assessment
Psychologist /
Psychosocial interventions Psychosocial interventions Continuing treatment
Therapist
Patient Associations
Aid recognition & self-diagnosis Raise awareness of options & “own” patient groups Continuing care
/ Social Care
Payers Develop / approve / enforce clinical guidelines and reimbursement / pricing decisions
Psychologist /
Psychosocial interventions Psychosocial interventions Continuing treatment
Therapist
Psychiatrist /
• Combine ADDs Management &
Specialist Mental Specialist / enhanced care
• Augment therapy continuing care
Health Services
Patient Associations
Aid recognition & self-diagnosis Raise awareness of options & “own” patient groups Continuing care
/ Social Care
Payers Develop / approve / enforce clinical guidelines and reimbursement / pricing decisions
Rx competition1
Patients buying (m.) Sales (b. $) Price ($ for full year of usage2)
10 10
9 Pipeline: Antibodies 13.730
8 8
7 Pipeline: Small molecules 1.805
6 6
5
ACHE inhibitors 1.145
4 4
3
2 2 NMDA antagonist 1.436
1
0 0 Generic ACHE inhibitors 359
2012 2021 2012 2021
• Alzheimer’s: A progressive disease with changes in intellectual and Healthy Brain with
brain Alzheimer’s
social skills interfering with day-to-day life, caused by death/
degeneration of nerve and nerve cells
• Mild Cognitive Impairment: A stage between forgetfulness due to age
and dementia, with minimal changes to daily activities, caused by a
lesser degree of the types of brain changes in AD
4
We will mobilize a team of senior and highly experienced
A.T. Kearney consultants with intimate knowledge of MoH
A.T. Kearney team & SMEs1
Laskina Health
Jonathan • Over 20 years of industry and Mental Health • Development of several screening
Anscombe consulting experience with focus programs
Partner on the healthcare sector William
• More than 40 years of experience in
Global Experts
Hyslop
healthcare serving in leading positions
Oncology
Jerry Cacciotti • Over 20 years of management
consulting experience in Laurie
Partner biopharma and healthcare strategy Glimcher • 20+ years of experience in oncology
Oncologyert now serving as CEO of Harvard Cancer
center
4
We have built an intimate knowledge of MoH and MoH key
stakeholders through four engagements in the past 2 years
A.T. Kearney knowledge of MoH
Insurance and Purchasing of For a GCC Ministry of Health designed the 2017
A Healthcare Services strategy, structure and implementation plan for
the payer-provider split
Chronic Model Pilot Detailing and piloting of the new approach to 2017
treating Chronic patients
C
Roll out plan for the Model of Care Develop the national rollout plan for the piloted 2018
Model of Care pathways, including a national
D strategy, a plan to adjust pilot implementation
based on each region/cluster particularities
and the estimated budget required
5
We will engage project team members from MoH VRO with a
collaborative and co-creating working style
A.T. Kearney collaborative style of work
Cooperation and continuity Client’s involvement Know-how sharing & Coaching
MoH &
project
leadership
A.T. Kearney
Co- MoH VRO
creation A.T. Kearney
• We work with our clients – not on • We work “side-by-side” with our • A.T. Kearney consultants will be
our clients, to deliver immediate clients to drive change straight sharing their know-how with
impact and growing advantage from day one MoH VRO managers
• Develop new ways of interacting • Strong internal buy-in and drive • Strong interaction during
with clients adapting the to change project
approach to specific needs
5
A.T. Kearney is known for delivering real impact early in the
project and supporting clients until the “Work is done”
A.T. Kearney way of working
A.T. Kearney Positioning vs. Competition Our Approach and Philosophy
+
“Pure Strategy Our
consulting firms” A.T. Kearney Promise Immediate Impact, Growing Advantage
(e.g. McKinsey) “Strategy and
concepts into
tangible results”
Strategy
“Implementation How we
oriented consulting deliver
firms” (e.g. Booz&Co)
Forward-
Collaborative Authentic
“Big Four” thinking
(e.g. KPMG)
• Strategic reasoning • Pragmatic approach
“Technical • Content leadership • Results orientated
consulting firms”
(e.g. Detecon)
• Collaborative and • International benchmarks
pragmatic working style • Industry experienced
• Adapting to the local people
- Implementation + culture • Hands-on support
Mohamed Berrada
Mohamed.Berrada@atkearney.com
A.T Kearney Saudi Limited
King Faisal Foundation Building
South Tower, 7th Floor, Office FS07A
King Fahad Highway, Olaya District
Riyadh, Saudi Arabia
Americas Atlanta Boston Chicago Detroit Mexico City San Francisco Toronto
Bogotá Calgary Dallas Houston New York São Paulo Washington, D.C.